Thursday, July 30, 2009

Publicis Cuts 4% - And Lied About It

BNET's Jim Edwards posted a shocking article today that announced Publicis CEO Maurice Levy outright lied - to clients, to employees, to shareholders -about the status of layoffs across the French holding company. (The Guardian originally broke the story here.)

I'd blogged in the past about WPP and Omnicom layoffs, so I thought it would be only fair to mention the latest Publicis revelation as well. But this goes beyond just the fact they've had layoffs. Their own global leadership lied by ommission. Is anyone else disgusted by this? What else would they be willing to lie about? What kind of tone does this set for the entire company and all its many agencies? And I'm curious if clients have seen any drop in service or turnaround time as a result of the layoffs, yet didn't know why ...

BNET's apparently been keeping track of ad agency layoffs; here are their holding company layoff stats as of July 30:
  • WPP - up to 7,200

  • Omnicom - 3,500

  • Interpublic - 3,000

  • Publicis - 1,800

  • The Nielsen Co. - 1,600

  • Aegis - 780

The BNET Ad Agency Layoff Counter also breaks out the numbers by individual agency, if you're interested. The list does include agencies that tend to swing "pure digital" like Digitas and Razorfish.

Intouch is not on the list; we haven't had layoffs. But we work with a lot of these agencies and many of our associates (myself included) have been a part of these holding co's in the past. I truly am sorry for the jobs lost and the individuals affected. I hope the positive news we've been hearing lately about the economy hitting bottom and starting to turn around will help generate the jobs to help find these folks a new home.

Interested to learn more about my perspective on big agencies and big holding companies, and the advantages of being an independent agency like us? Here are a few of my favorite related past posts:

>> The Collaborative Agency Model
>> Why It's Great to Be An Independent Agency
>> WPP Agencies Ready Layoffs
>> Innovation Trumps Size

Wednesday, July 29, 2009

Do you Binghoo!? (or YaBing?)

With special thanks to Chris Nelson, Director - Digital Engagement Intelligence & Operations, for this timely update!

Hell has frozen over. Microsoft and Yahoo! have struck a search deal.

Do you Binghoo!?

It’s a 10-year agreement in which Bing will power Yahoo! Search. This is a very interesting deal because it would give Binghoo! a combined 28.4% search market share according to comScore. Note: Google remains consistent at 65% share.

Details of the deal include:

  • Microsoft will have the ability to leverage Yahoo! search technologies into it’s search engine algorithms.
  • Yahoo! will sell the search advertising for the combined entities.
  • AdCenter (Bing’s advertiser interface) will be the self-service ad platform.
  • Microsoft will pay Yahoo! 88% of search ad revenue generated by Yahoo! sites. Yahoo! is anticipating nearly $275 million in revenue as a result.
  • Display advertising (banners, video ads, etc.) is not part of the deal.
More information can be found from SearchEngineWatch and Mashable.

What's This Mean for Pharma?
Historically in our experience with pharma pay-per-click (PPC), MSN’s cost-per-click (CPC) and click-through rates have been noticeably better than Yahoo’s, with a few exceptions. Primarily because of the fact that Yahoo! has more advertisers. And, Yahoo! (logically) has more advertisers because of their larger search share.

Danny Sullivan (Editor-in-Chief - Search Engine Land and a famous SEM guru) is currently conducting a survey on Twitter. Per a Tweet at 9:30 CT today - 2/3 of his respondents say the deal will hurt Yahoo! in the long-run. So, it will be interesting to see how things shake out over the next few months.

Tuesday, July 28, 2009

100 Sites and Growing

We went through a fun exercise recently to collect and list all of the pharma Web sites that our agency created, developed, host, and/or maintain. Because we focus exclusively on digital marketing for pharmaceutical companies, the list is long.

Just counting sites that are currently live, we have more than 100 live pharma-related Web sites. That doesn't include sites under development or the countless sites that have come and gone over the past 10 years of our company's existence. Our list of sites represents quite the study in Web site variety:
  • Audience. Of course many of our sites are designed to deliver information to consumers and healthcare professionals. But healthcare professionals aren't just physicians; there are sites for nurses, pharmacists, formulary professionals, and clinical trial investigators, among others. Several of the sites aren't public-facing, but instead may be intranets for pharma company associates, extranets for KOLs, slide libraries for MedInfo teams, online resources for sales reps ... the list goes on.
  • Purpose. It goes without saying that the 100+ sites represent almost as many disease categories. But they also represent a wide variety of objectives: education, awareness, lead acquisition, product information, community-building, brand loyalty/retention, public affairs, patient empowerment, online ordering, clinical trial investigator recruitment, internal communications, story-sharing... the list goes on.
  • Size and Functionality. I guess technically, even a single landing page could be considered a Web site, however, we didn't include those in our list. But there is still a pretty vast variety of sites big and small, shallow and deep, interactive and static. Sites with video, audio, animation, and interactive tools. Skinny sites for just-launched products, and massive portal sites for in-depth learning.
  • Agency Roles. Many of these sites were concepted, designed, written, built, analyzed, and optimized entirely by Intouch Solutions. And, depending on the client, other sites may have had many agency fingers touching them ... one agency did the design, another did the build, another did SEO, another designed the CRM component ... (guess which model is the most effective and efficient?)
Sorry I can't publish the list here. But I can offer up some good rules to live by when thinking about your Web sites:
  1. Make sure your site has a purpose. Is it database capture? Awareness? Education? Recruiting? What's the call to action? And how exactly are you measuring against these goals? All of this needs to be agreed upon before a single concept is designed or a line of code is written.
  2. Don't let your site die a slow death. Sadly, there are some sites on our list that are several years old, and haven't been redesigned or updated since their launch. It shows. Not only visually, but in the analytics. You've heard this before, but if you keep the design, usability, and content fresh, your users will follow. See #4.
  3. Think beyond the typical consumer and HCP site. Who are some key secondary audiences that you've been wanting to reach? What information of value can you offer them? In our experience, HCPs such as nurses and pharmacists appreciate customized content and the attention and respect from pharma they often don't receive.
  4. Analyze and optimize. So many marketers make the mistake of going through the motions of creating a Web site, launching it (hooray!) and then letting it sit. I can't blame them, actually, when taking a Web site through legal, medical, regulatory review can feel like the equivalent of birthing octuplets. But Octo-mom aside, launching a site is really only the first step. Web analytics can reveal infinite amounts of information that will help you optimize your site to work harder and smarter for you and your goals. This is really the only channel where you have that much ongoing information and flexibility - why not take advantage of it?
  5. Have the right partner. Don't be afraid to ask your agency how much pharma experience they have, how many Web sites they have designed/written/built, how many technical-based employees they have on staff, what - if anything - do they outsource, etc. For more questions to ask your digital agency, see this past blog post.

Finally, one tip unrelated to your Web sites
At Intouch, we love the Web, and we certainly love Web sites. But we are also constantly reminding our clients to consider what's happening outside your site. Where your audience is visiting, what they're reading, what information they are seeking. It can't be just about your site ... these days, marketers really have to consider the entire Web experience. Give your brand lots of legs online, and you'll be where your customers are, whomever they may be.

Friday, July 17, 2009

Fiber and Pharma can be Funny

Fiber can be funny ... especially when it makes fun of pharma advertising.

Kudos to the Fiber One folks for this fun effort, a campaign that pokes fun at pharma advertising and fake diseases, complete with legal disclaimers.

Personally, it seems like a pretty vast, expensive effort and not sure what the return has been for them, but the fact that (a) I learned about it from an email from a client and (b) I'm now posting it on my blog proves the following:

> Word of mouth works

> If you do it right, viral works

> Microsites can be a powerful way to bring a concept to life

> Pharma folks can be funny, too. See past posts for some of my favorite pharma humor here.

Thursday, July 16, 2009

Shifting Trends in Pharma Marketing

I love stats! Doubleclick recently provided a June 2009 report to us on some research conducted by ORC Guidelines. The report, titled The “E-Dimensions” of Pharmaceutical Advertising, looks at "continually shifting trends of pharmaceutical marketing in the interactive space to determine whether marketers are able to deliver the information consumers are looking for in a way that meets the requirements and expectations of an “e-society.”'

While the research study was small, there were some salient points that emerged that were worth sharing:
  • 47% of those surveyed that saw an online ad for an Rx ended up going to the product website
  • 77% agreed that mentioning the advertising to their doctor resulted in a better discussion

  • With regards to representation of safety information – one in four respondents indicated there is too much emphasis on the risk
  • The majority of consumers would rather be exposed to a condition-specific message rather than product-specific (see past blog posts on trends in unbranded marketing)
  • Currently one in three pharmaceutical companies are currently using some type of emerging media for their DTC communications – and this number is expected to double in three years
All food for thought as you kick in gear for your 2010 planning. Wow, is it that time already?
Special thanks to Doubleclick for the data, and to our Media Director, Tina, for the key points!